GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Total Equity

Albireo Pharma (FRA:BDQM) Total Equity : €101.07 Mil (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Total Equity?

Albireo Pharma's total equity for the quarter that ended in Sep. 2022 was €101.07 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Albireo Pharma Total Equity Historical Data

The historical data trend for Albireo Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Total Equity Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.14 107.80 83.85 148.97 155.41

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.46 155.41 134.55 107.54 101.07

Albireo Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Albireo Pharma's Total Equity for the fiscal year that ended in Dec. 2021 is calculated as

Total Equity=Total Assets(Q: Dec. 2021 )-Total Liabilities(Q: Dec. 2021 )
=267.315-111.902
=155.41

Albireo Pharma's Total Equity for the quarter that ended in Sep. 2022 is calculated as

Total Equity=Total Assets(Q: Sep. 2022 )-Total Liabilities(Q: Sep. 2022 )
=324.434-223.363
=101.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albireo Pharma Total Equity Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Total Equity
Comparable Companies
IGMS KNSA ALLO RGNX COGT QURE MRUS VKTX ARQT RAPT OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX SGEN HKSE:02269 OCSE:GMAB
Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Website
https://www.albireopharma.com
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines